Tune Therapeutics
Brian Cosgrove has worked in the field of bioengineering since 2008. Brian began as an Undergraduate Researcher in the Henderson Lab at Syracuse University in 2008. Brian then moved to the University of Pennsylvania in 2011, where they were a Bioengineering PhD Student. In 2017, they became a Postdoctoral Fellow in the Gersbach Lab at Duke University. In 2021, they joined Tune Therapeutics as a Principal Scientist and Senior Scientist.
Brian Cosgrove received their Bachelor of Science in Bioengineering (Biomechanics) from Syracuse University in 2011. Brian then went on to pursue a PhD in Bioengineering (Mechanobiology, Biomaterials, Stem Cell Biology) at the University of Pennsylvania, which they completed in 2017.
Tune Therapeutics
1 followers
With its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine. With deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.